TOP TIERMARKET NEWSWIRE
News & sentiment

CLIMB BIO INC (CLYM) — News & AI sentiment

CLIMB BIO INC (CLYM) news roundup. 4 stories in the past week, 24 over 30 days. Average 30-day sentiment is 60/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $407K — net selling of $407K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
4
avg sentiment 61.5/100
30d stories
24
avg sentiment 60/100
Insider net (90d)
$407K
0 buys · 1 sells
Congress (90d)
0
0 buys · 0 sells

CLYM news in the last 24 hours, 7 days, 30 days and 90 days

How much CLYM coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowCLYM storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days461.5/100CLYM headlines →
Last 30 days2460/100CLYM headlines →
Last 90 days3159.5/100CLYM headlines →

Latest stories on CLYM

5d ago
H.C. Wainwright raises Climb Bio stock price target on drug data
Investing.com Analyst Ratings61 · neutralanalyst
5d ago
Oppenheimer raises Climb Bio stock price target on IgAN data
Investing.com Analyst Ratings63 · neutralanalyst
6d ago
6d ago
Sep 4
Sep 4
BTIG raises Climb Bio stock price target to $32 on phase 1 data
Investing.com Analyst Ratings61 · neutralanalyst
Sep 3
Sep 3
Baird raises Climb Bio stock price target to $25 on trial data
Investing.com Analyst Ratings61 · neutralanalyst
Sep 3
Sep 3
Sep 3
Sep 3
Sep 3
Why is Climb Bio stock sliding today?
Investing.com Markets42 · neutralgeneral
Sep 3
Sep 3
Climb Bio, Inc. (CLYM) files 8-K
SEC 8-K50 · neutralgeneral
Sep 3
Climb Bio stock surges 17% on positive drug trial results
Investing.com Markets73 · bullishproduct/pr
Sep 3
Sep 3
Sep 3
Sep 3
Sep 2
Sep 2
Climb Bio stock price target raised to $24 by H.C. Wainwright
Investing.com Analyst Ratings61 · neutralanalyst
Aug 24
Aug 24
Climb Bio, Inc. (CLYM) files 8-K
SEC 8-K50 · neutralgeneral
Aug 14
Open CLYM in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →